Table 4

Best tumor response in cycle 1 per independent radiologic assessment

Patient response rateCohorts I + IIICohort IITotal
Evaluable patients, n* 20 1 21 
 Overall response rate, n (%)† 8 (40.0) 1 (100.0) 9 (42.9) 
 Best overall response, n (%)    
  CR 4 (20.0) 0 (0.0) 4 (19.0) 
  PR 4 (20.0) 1 (100.0) 5 (23.8) 
  Stable disease 2 (10.0) 0 (0.0) 2 (9.5) 
  Progressive disease 10 (50.0) 0 (0.0) 10 (47.6) 
    
All patients, n 23 2 25 
 Overall response rate, n (%)† 8 (34.8) 1 (50.0) 9 (36.0) 
 Best overall response, n (%)    
  CR 4 (17.4) 0 (0.0) 4 (16.0) 
  PR 4 (17.4) 1 (50.0) 5 (20.0) 
  Stable disease 3 (13.0) 0 (0.0) 3 (12.0) 
  Progressive disease 10 (43.5) 0 (0.0) 10 (40.0) 
  No response assessment 2 (8.7) 1 (50.0) 3 (12.0) 
Patient response rateCohorts I + IIICohort IITotal
Evaluable patients, n* 20 1 21 
 Overall response rate, n (%)† 8 (40.0) 1 (100.0) 9 (42.9) 
 Best overall response, n (%)    
  CR 4 (20.0) 0 (0.0) 4 (19.0) 
  PR 4 (20.0) 1 (100.0) 5 (23.8) 
  Stable disease 2 (10.0) 0 (0.0) 2 (9.5) 
  Progressive disease 10 (50.0) 0 (0.0) 10 (47.6) 
    
All patients, n 23 2 25 
 Overall response rate, n (%)† 8 (34.8) 1 (50.0) 9 (36.0) 
 Best overall response, n (%)    
  CR 4 (17.4) 0 (0.0) 4 (16.0) 
  PR 4 (17.4) 1 (50.0) 5 (20.0) 
  Stable disease 3 (13.0) 0 (0.0) 3 (12.0) 
  Progressive disease 10 (43.5) 0 (0.0) 10 (40.0) 
  No response assessment 2 (8.7) 1 (50.0) 3 (12.0) 
*

Patients were evaluable if they had received study drug for at least 1 wk at the target dose (112 μg/d) or if study drug was stopped earlier because of progressive disease.

†

CR or PR.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal